Compare Amgen, Inc. (AMGN) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Warner Music Group Corp — how do they compare? Amgen, Inc. trades at $415.5 (market cap $224.14B), while Warner Music Group Corp trades at $24.57 (market cap $13.12B). The key difference: Amgen, Inc. is far larger — about 17.1× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| AMGN | WMG | |
|---|---|---|
Market Cap | $224.14B | $13.12B |
Sector | Health | Media |
52-Week High | $417.20 | $34.72 |
52-Week Low | $271.18 | $23.65 |
Enterprise Value | $267.45B | $17.42B |
Dividend Yield | 2.43% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Warner Music Group (WMG) trades at $24.62, down 6.78% in the past 24 hours, reflecting bearish technical momentum. The stock shows mixed fundamentals with recent earnings beats in Q1 and Q2 2026 but declining net income margins from 9.3% in 2022 to 5.44% in 2025. Strong institutional buying interest and a 66.66% analyst buy rating provide support despite near-term weakness.
WMG presents a compelling value opportunity with reasonable valuation multiples (P/E 20.06, P/S 1.8) and robust 9.2% projected 2026 net margin. Key risks include leadership transitions following the CFO's departure and streaming market competition, but strategic partnerships and price increases support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
